Purchase this article with an account.
Rachel Lee, Tak Yee Tania Tai; Epidemiology of Neovascular Eye Diseases and Associated Glaucomas in the United States: 2006 Compared with 2016. Invest. Ophthalmol. Vis. Sci. 2019;60(9):1964.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The purpose of this study is to investigate the epidemiology of neovascular eye diseses and associated glaucomas seen and treated by physicians in the United States in 2006 compared to 2016, as the standard treatments for these diseases changed over this period of time.
The Centers for Medicare and Medicaid Services Research Data Distribution Center provide Medicare research identifiable files that contain a simple random sample of 5% of all Medicare beneficiaries. The files provide data on beneficiary demographics, insurance coverage, and can be linked to associated claims files. Claims files include date and place of service, associated International Classification of Diseases, 9th edition, Clinical Modification (ICD-9-CM and ICD-10) diagnoses, and Current Procedural Terminology (CPT) codes.Statistical analysis was completed using SAS 9.4 software.
Based on the 5% sample of Medicare claims in 2006 and 2016, respectively revealed an increase in the number of Medicare claims related to central retinal venous occlusions (CRVO), proliferative diabetic retinopathy (PDR), and glaucoma in 2016 as compared to 2006. While CRVO, PDR, and glaucoma accounted for 469, 945, and 193 Medicare claims in 2006, each of these diagnoses accounted for at least 50-fold as many Medicare claims in 2016.Comparison of Medicare claims data in 2006 and 2016 revealed a significant increase in the number of intravitreal injections, including those associated with a diagnosis of central retinal vein occlusion (7 in 2006 to 6,078 in 2016), proliferative diabetic retinopathy (4 in 2006 to 57,929 in 2016), and glaucoma (1 in 2006 to 676 in 2016.)
Neovascular retinopathies and glaucoma are both account for significantly increased number of Medicare claims in 2016 compared to 2006. This is associated with a marked increase in intravitreal injection claims over this period of time.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
This PDF is available to Subscribers Only